Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?”
Crossref DOI link: https://doi.org/10.1007/s40259-018-0330-1
Published Online: 2019-01-02
Published Print: 2019-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Niazi, Sarfaraz K. http://orcid.org/0000-0002-0513-0336
Text and Data Mining valid from 2019-01-02
Article History
First Online: 2 January 2019
Compliance with Ethical Standards
:
: No funding was received.
: Sarfaraz K. Niazi has no conflicts of interest.